References
Abshagen U. A new molecule with vasodilating and β-adrenoceptor blocking properties. Journal of Cardiovascular Pharmacology 10 (Suppl. 11): 23–32, 1987
Anderton JL, Vallance BD, Stanley NN, Crowe PF, Mittra B, et al. Atenolol and sustained release nifedipine alone and in combination in hypertension. A randomised, double-blind, crossover study. Drugs 35 (Suppl. 4): 22–26, 1988
Daniels AR. Opie LH. Atenolol plus nifedipine for mild to moderate hypertension after fixed doses of either agent alone. American Journal of Cardiology 57: 965–970, 1986
de Devitiis O, Petitto M, Di Somma S, Galderisi M, Villari B, et al. Nitrendipine and atenolol: comparison and combination in the treatment of arterial hypertension. Arzneimittel-Forschung 35: 727–729, 1985
Ekelund L-G. Nifedipine in combination therapy for chronic hypertension. American Journal of Medicine 79 (Suppl. 4A): 41–43, 1985
Heber ME, Brigden GS, Caruana MP, Lahiri A, Raftery EB. Carvedilol for systemic hypertension. Journal of Cardiovascular Pharmacology 10 (Suppl. 11): 113–118, 1987
Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The 1984 Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Archives of Internal Medicine 144: 1045–1057, 1984
Maclean D. Aims of combination therapy — improved quality of life or better blood pressure control? Drugs 35 (Suppl. 4): 16–21, 1988
Morgan T, Snowden R, Butcher L. Effect of carvedilol and metoprolol on blood pressure, blood flow and vascular resistance. Journal of Cardiovascular Pharmacology 10 (Suppl. 11): 124–129, 1987
Ogihara T, Ikeda M, Goto Y, Yoshinaga K, et al. The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension. Journal of Cardiovascular Pharmacology 10 (Suppl. 11): 108–112, 1987
Ogihara T, Goto Y, Yoshinaga K, Kumahara Y, Iimura O, et al. Dose-effect relationship of carvedilol in essential hypertension. Drugs 36 (Suppl. 6): 75–81, 1988
Opie LH, Lee J, White D. Antihypertensive effects of nifedipine combined with cardioselective beta-adrenergic receptor antagonism by atenolol. American Heart Journal 104: 606–612, 1982
Schnurr E, Widmann L, Glocke M. Efficacy and safety of carvedilol in the treatment of hypertension. Journal of Cardiovascular Pharmacology 10 (Suppl. 11): 101–107, 1987
Sorkin EM, Clissold SP, Brogden RN. Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 30: 182–274, 1985
Sponer G, Bartsch W, Strein K, Müller-Beckmann B, Bohem E. The pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties. Journal of Cardiovascular Pharmacology 9: 317–327, 1986
Takabatake T, Ohta H, Yamamoto Y, Ishida Y, et al. Combination therapy with an alpha- and beta-blocking agent, amosulalol and a calcium antagonist, nicardipine in essential hypertension. Clinical Report 20: 311–317, 1986
Takenaka T, Handa J. Cerebrovascular effects of YC-93, a new vasodilator, in dogs, monkeys and human patients. International Journal of Clinical Pharmacology and Biopharmacology 17: 1–11, 1979
Wathen CG, Hannan WJ, Turnbull LW, Muir AL. Afterload reduction by nifedipine — the acute haemodynamic response to exercise in hypertensive subjects. European Heart Journal 6: 358–364, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takabatake, T., Ohta, H., Yamamoto, Y. et al. Combination Therapy with Carvedilol and Nicardipine in Essential Hypertension. Drugs 36 (Suppl 6), 124–128 (1988). https://doi.org/10.2165/00003495-198800366-00021
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198800366-00021